Editas Medicine (EDIT) Doses the First Patient in the Mid-Dose Cohort of the BRILLIANCE Trial - Raymond James
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse reiterated a Market Perform rating on Editas Medicine (NASDAQ: EDIT) after the company announced dosing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
